25 related articles for article (PubMed ID: 34086262)
1. Validation of the Bethesda System for Reporting Thyroid Cytopathology in a Danish tertiary centre.
Madsen SH; Jespersen ML; Bonnema SJ; Rolighed L; Swan KZ
Dan Med J; 2024 May; 71(6):. PubMed ID: 38847411
[TBL] [Abstract][Full Text] [Related]
2. American Association of Clinical Endocrinology And Associazione Medici Endocrinologi Thyroid Nodule Algorithmic Tool.
Garber JR; Papini E; Frasoldati A; Lupo MA; Harrell RM; Parangi S; Patkar V; Baloch ZW; Pessah-Pollack R; Hegedus L; Crescenzi A; Lubitz CC; Paschke R; Randolph GW; Guglielmi R; Lombardi CP; Gharib H
Endocr Pract; 2021 Jul; 27(7):649-660. PubMed ID: 34090820
[TBL] [Abstract][Full Text] [Related]
3. Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis.
Tessler I; Leshno M; Feinmesser G; Alon EE; Avior G
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765745
[TBL] [Abstract][Full Text] [Related]
4. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
5. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
6. Consistency in the Distribution of Bethesda System for Reporting Thyroid Cytology Categories Over 9 Years: A Single Institute, Retrospective Study.
Harris M; Zloczower E; Pinhas S; Allon R; Zornitzki T; Malka L; Cohen Y; Lahav Y; Cohen O
Endocr Pract; 2024 Jun; 30(6):546-550. PubMed ID: 38570016
[TBL] [Abstract][Full Text] [Related]
7. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
8. Outcomes of the Bethesda system for reporting thyroid cytopathology: Real-life experience.
Avior G; Dagan O; Shochat I; Frenkel Y; Tessler I; Meir A; Jaffe A; Cohen O
Clin Endocrinol (Oxf); 2021 Mar; 94(3):521-527. PubMed ID: 32981060
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of the Bethesda system for reporting thyroid cytopathology in community- vs. institution-performed cytology.
Tessler I; Cohen O; Shochat I; Teitelbaum T; Dagan O; Meir A; Jaffe A; Avior G
Am J Otolaryngol; 2022; 43(2):103341. PubMed ID: 34968817
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
[TBL] [Abstract][Full Text] [Related]
11. Positive Correlation of Thyroid Nodule Cytology with Molecular Profiling-a Single-Center Experience.
Tessler I; Shochat I; Cohen O; Meir A; Avior G
Endocr Pathol; 2021 Dec; 32(4):480-488. PubMed ID: 34086262
[TBL] [Abstract][Full Text] [Related]
12. Molecular cytopathology for thyroid nodules: A review of methodology and test performance.
Nishino M
Cancer Cytopathol; 2016 Jan; 124(1):14-27. PubMed ID: 26348024
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
